Retrograde Application of Bone Marrow Aspirate Concentrate
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
The aim of our prospective randomised study is to assess the efficacy of the retrograde
application of non-selected bone marrow autologous cells concentrate (BMAC) in patients with
heart failure with reduced ejection fraction of left ventricle (HFREF) of ischemic aetiology.
The evaluated preparation is concentrated BMAC, obtained using Harvest SmartPReP2 technology.